CD3+ Gene Expression Monitoring for Low-Dose Naltrexone
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a simple method to monitor the effective administration of naltrexone or its metabolites/analogs in cancer treatment to ensure optimal dosage and minimize side effects, as traditional methods struggle to determine if the drug is being administered at an effective level.
Innovation Solution
Monitoring gene expression profiles of specific genes in CD3+ cells, such as those listed in Tables 1 and 2, to determine if naltrexone or its metabolites/analogs are being administered at an effective low dose, which enhances immune system priming and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naltrexone is administered at high doses, then immune suppression occurs and therapeutic efficacy decreases, but if administered at low doses, then effective immune priming is achieved. The problem is determining the effective low dose level
Solution Approach 1:
The patent implements a feedback mechanism by measuring gene expression levels in CD3+ cells to determine whether naltrexone is being administered at an effective low dose. The method monitors the expression of specific genes (such as GITR, ICOS, CD28) and uses this information to adjust the dosage, creating a closed-loop control system that ensures optimal therapeutic effect while avoiding immune suppression associated with high doses.
2Reliability
If traditional cancer therapies are administered at high doses, then therapeutic effect increases, but negative side effects are exacerbated
Solution Approach 1:
The patent changes the dosage parameter of naltrexone from conventional high doses to low doses (e.g., 0.5-5 mg/day), which fundamentally alters the therapeutic mechanism from immune suppression to immune priming. This parameter change enables achieving therapeutic effect while minimizing harmful side effects, as the low dose regime activates beneficial immune pathways without causing the adverse effects associated with high dose immunosuppression.
3Adaptability or versatility
If naltrexone dosage is not optimized, then treatment effectiveness varies between patients, but implementing monitoring increases treatment complexity
Solution Approach 1:
The patent employs a self-service approach where the patient's own CD3+ cells serve as the monitoring system. By measuring gene expression levels in the patient's immune cells, the method enables personalized dosage optimization without requiring external monitoring infrastructure. The biological system itself provides the feedback signal through gene expression patterns, eliminating the need for complex external monitoring devices.
Data Source
AI summary
The invention relates to a method for monitoring the treatment of a subject undergoing therapy with an active that is naltrexone or a metabolite or analogue thereof, comprising:measuring the gene expression profile of any of the genes listed in Table 1 or Table 2, in a sample of CD3+ cells obtained from the subject undergoing treatment;wherein if the expression of any of the genes in Table 1 is increased compared to a control, or if any of the genes listed in Table 2 is decreased compared to a control the active is being administered at an effective level.